← Back to Search

Corticosteroid

Miricorilant for Weight Gain

Phase 2
Waitlist Available
Research Sponsored by Corcept Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline day1 to week 12
Awards & highlights

Study Summary

This study is evaluating whether a drug may help reduce weight in individuals with schizophrenia.

Eligible Conditions
  • Weight Gain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline day1 to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline day1 to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in body weight at Week 12 for 600 mg miricorilant versus placebo
Incidence of adverse events (AEs), serious AEs (SAEs), and AEs leading to early discontinuation
Secondary outcome measures
Change from baseline in Homeostatic model assessment for insulin resistance (HOMA-IR) at Week 12
Change from baseline in waist-to-hip ratio at Week 12
Percentage of patients achieving more than or equal to 5% weight loss

Side effects data

From 2022 Phase 2 trial • 50 Patients • NCT04466215
12%
Fatigue
12%
Headache
8%
Abdominal distension
8%
Feeling less euphoric
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CORT118335

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CORT118335- 600 mgExperimental Treatment1 Intervention
Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Miricorilant
2021
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor
68 Previous Clinical Trials
6,309 Total Patients Enrolled
5 Trials studying Weight Gain
406 Patients Enrolled for Weight Gain
Kavita Juneja, MDStudy DirectorCorcept Therapeutics
4 Previous Clinical Trials
393 Total Patients Enrolled
1 Trials studying Weight Gain
151 Patients Enrolled for Weight Gain
Ada Lee, MDStudy DirectorCorcept Therapeutics
5 Previous Clinical Trials
274 Total Patients Enrolled
1 Trials studying Weight Gain
151 Patients Enrolled for Weight Gain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
2019. "This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03818256.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top